What is the Market Size of Biosimilars | Insights, Trends & Growth Analysis 2026

What is the size of Biosimilars Market?

This growth is mainly driven by the increasing acceptance of lower-cost biologic alternatives, the increasing incidence of chronic and autoimmune diseases increasing the use of biologics, and the resulting increased regulatory approvals of biologics, particularly biosimilars, opened the door to wider access.

Growth Factors for Biosimilars Industry

• Increasing patent expirations of blockbuster biologics provide opportunities for entry for biosimilar manufacturers and increase access to treatment options.
• An increasing focus on healthcare cost containment by payers and providers is driving them to recognise biologic therapy.
• The increasing prevalence of oncology and autoimmune diseases is driving the demand for biologic therapies and alternatives to biologics, biosimilars.
• Advances in manufacturing scale-up capacity, CMO and CDMO partnerships promote the scalability of the biosimilar product.
• The estimated time to market related to the approval of biosimilars is expected to shorten due to faster and the introduction of interchangeable designations for biosimilar products.

Biosimilars Market Trends

Trends for the biosimilar market suggest we are approaching the tipping point for increased uptake of biosimilar monoclonal antibodies and immunomodulators as lower-cost treatment options. Manufacturers are extending their portfolios beyond oncology into the treatment of autoimmune and inflammatory conditions. Additionally, alliances between manufacturers, licensing agreements with pharmaceutical companies to access proprietary biologics, and increased domestic capacities for manufacturing are all accelerating product launches and access by regions.

Emerging Developments in the Biosimilars Market

The Biosimilars Market developments include advanced manufacturing innovations such as next-generation cell-culture platforms and bioprocess optimisation, enabling lower cost-of-goods and driving competitive pricing. Pipeline expansions are targeting newer therapeutic areas including ophthalmology and neurology for biosimilar entry. Additionally regional expansion into developing markets is gaining momentum as companies seek to leverage favourable reimbursement frameworks and partnerships with local players.

List of Leading Companies in the Biosimilars Market

Some of the leading companies include:

• Pfizer Inc.
• Novartis AG (Sandoz)
• Amgen Inc.
• Samsung Bioepis Co., Ltd.
• Coherus Biosciences Inc.
• Takeda Pharmaceutical Company Limited
• Merck KGaA

Frequently Asked Questions About the Market Study (FAQs):